Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 7/20 | 0.36 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.36 |
| ▸ | OXTR | P30559 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | UBE2M | P61081 | 1/20 | 0.34 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30930374 | 0.94 | MCHR1 (0.36) | MCHR1OXTRMEN1PABPC1KMT2A | |
| SCHEMBL30930328 | 0.91 | MCHR1 (0.38) | MCHR1OXTRMEN1PABPC1KMT2A | |
| SCHEMBL30930351 | 0.90 | MCHR1 (0.36) | MCHR1LTC4SOXTRMEN1PABPC1 | |
| SCHEMBL30930466 | 0.90 | MCHR1 (0.36) | MCHR1LTC4SOXTRMEN1PABPC1 | |
| SCHEMBL30930428 | 0.88 | MEN1 (0.38) | MCHR1OXTRMEN1PABPC1KMT2A | |
| SCHEMBL30930463 | 0.88 | MEN1 (0.38) | MCHR1OXTRMEN1PABPC1KMT2A | |
| SCHEMBL30930420 | 0.86 | SMN1; SMN2 (0.36) | MCHR1OXTRMEN1PABPC1KMT2A | |
| SCHEMBL30930454 | 0.85 | MEN1 (0.38) | MCHR1OXTRMEN1PABPC1KMT2A | |
| SCHEMBL30930461 | 0.85 | MEN1 (0.36) | MCHR1OXTRMEN1PABPC1KMT2A | |
| SCHEMBL30930422 | 0.84 | OXTR (0.36) | MCHR1OXTRMEN1PABPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118103363-A | Novel capsid assembly inhibitor | 南韩商AM科学股份有限公司 | 2024-05-28 | — | — | CN | claimed |
| US-20250009742-A1 | NOVEL CAPSID ASSEMBLY INHIBITORS | META-IMMUNE, INC. (KR) | 2025-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250009742-A1 | NOVEL CAPSID ASSEMBLY INHIBITORS | ZC3HAV1, ZC3HAV1L, MAVS | MCHR1 3260/4885LTC4S 4691/4885OXTR 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.